Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.25
Bid: 24.00
Ask: 24.50
Change: -1.00 (-3.96%)
Spread: 0.50 (2.083%)
Open: 25.25
High: 25.25
Low: 24.25
Prev. Close: 25.25
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Mitchells & Butlers Down Amid Raise Plan

Thu, 07th Jan 2021 10:51

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.

----------

FTSE 100 - WINNERS

----------

J Sainsbury, up 3.8%. The grocer's like-for-like sales in the nine weeks to January 2 - so including the key festive period - were up 9.3% year-on-year. For the whole of its third-quarter, like-for-like sales, excluding fuel, climbed 8.6%. Including fuel, like-for-like sales were up a more modest 3.2%.

----------

FTSE 100 - LOSERS

----------

Experian, down 2.4%. The stock went ex-dividend, meaning new buyers no longer qualify for the latest payout.

----------

FTSE 250 - LOSERS

----------

Trainline, down 7.8%. Launched an offering of GBP150 million of senior unsecured convertible bonds due 2026. The train booking platform operator in UK said the net proceeds of the five-year bonds will "provide additional liquidity, protecting the business further in an extended Covid downturn".

----------

Mitchells & Butlers, down 7.0%. Reports sharp 67% sales fall for 14 weeks to January 2 and adds that it is mulling an equity raise.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Sareum Holdings, up 10%. The Cambridge-based drug developer said the US Patent Office approved its patent application for an invention associated with its SDC-1802 TYK2/JAK1 kinase inhibitor programme

----------

James Fisher & Sons, up 7.9%. The marine services provider saw improved trading in its fourth quarter, so now expects 2020 underlying profit to be at the upper end of its guided range.

----------

Synectics, up 4.9%. The Sheffield, England-based provider of security systems has successfully deployed the first phase of its operational management system for German railway operator S-Bahn in Berlin.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Ormonde Mining, down 29%. Adjourns annual general meeting scheduled for Thursday. The Spain-focused natural resources firm says this is so it can continue talks with its largest shareholder over motions six to eight, concerning its share capital and ability to make market purchases.

----------

Joules Group, down 6.1%. The retailer said sales in the seven months trading period to January 3 were better than expected, though in-store sales in the seven weeks to January 3 plunged 58%.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
7 Oct 2021 22:08

TRADING UPDATES: Marlowe buys; Galliford snaps up nmcn's Water unit

TRADING UPDATES: Marlowe buys; Galliford snaps up nmcn's Water unit

Read more
19 Aug 2021 14:25

IN BRIEF: Sareum expects annual loss to widen, increases R&D

IN BRIEF: Sareum expects annual loss to widen, increases R&D

Read more
19 Aug 2021 07:41

Sareum expects FY losses to widen on higher R&D costs, supply delays

(Sharecast News) - British drugmaker Sareum said on Thursday that it expects to post a widened full-year loss as a result of increased research-and-development expenditure and delays in compound supply.

Read more
9 Aug 2021 17:08

TRADING UPDATES: Netcall wins new deal; Sareum raises GBP1 million

TRADING UPDATES: Netcall wins new deal; Sareum raises GBP1 million

Read more
6 Aug 2021 15:00

Sareum positive on SRA737 outlook after Sierra call

(Sharecast News) - Specialist drug development company Sareum noted on Friday that Sierra Oncology, the licence holder for the novel Chk1 inhibitor 'SRA737', had discussed its newly-announced global in-licensing agreement with AstraZeneca for AZD5153 with investors, which is a novel BRD4 BET inhibitor, to expand its myelofibrosis pipeline.

Read more
30 Jul 2021 19:40

TRADING UPDATES: Capita and Custodian REIT agree disposals

TRADING UPDATES: Capita and Custodian REIT agree disposals

Read more
30 Jul 2021 11:00

AIM WINNERS & LOSERS: Sareum in patent boost; Airea flags uncertainty

AIM WINNERS & LOSERS: Sareum in patent boost; Airea flags uncertainty

Read more
19 Jul 2021 19:13

TRADING UPDATES: Sareum raises GBP1 million; Marlowe buys Core Stream

TRADING UPDATES: Sareum raises GBP1 million; Marlowe buys Core Stream

Read more
1 Jul 2021 19:26

TRADING UPDATES: Gym Group bulks up with placing; 88 Energy debt free

TRADING UPDATES: Gym Group bulks up with placing; 88 Energy debt free

Read more
1 Jul 2021 11:18

Sareum releases 'encouraging' results from Covid-19 research

(Sharecast News) - Specialist drug development company Sareum announced "encouraging" top-line results from its UKRI grant-funded Covid-19 research project on Thursday.

Read more
15 Jun 2021 20:28

TRADING UPDATES: Tremor Nasdaq IPO underway; MGC's CannEpil in Ireland

TRADING UPDATES: Tremor Nasdaq IPO underway; MGC's CannEpil in Ireland

Read more
1 Jun 2021 17:43

TRADING UPDATES: Breedon buys Micromix; Marlowe acquires Alarm

TRADING UPDATES: Breedon buys Micromix; Marlowe acquires Alarm

Read more
1 Jun 2021 11:30

AIM WINNERS & LOSERS: Sound Energy falls on Morocco tax notification

AIM WINNERS & LOSERS: Sound Energy falls on Morocco tax notification

Read more
25 May 2021 17:11

TRADING UPDATES: Mothercare sales down; Revolution Bars seeks to raise

TRADING UPDATES: Mothercare sales down; Revolution Bars seeks to raise

Read more
25 May 2021 10:56

Sareum's pre-clinical development of SDC-1801 delayed by Covid-19

(Sharecast News) - Pharmaceutical company Sareum said on Tuesday that Covid-19 has continued to impact the contract research organisations it was working to complete pre-clinical development of its SDC-1801 drug candidate for autoimmune disease.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.